In June, ChromoTek’s website is moving to

ChromoTek congratulates Proteintech on its 20th anniversary

“While we are proud of our progress as a company over the past couple decades, we are most proud of what our technology has done in the hands of scientists. We’ve seen more than 100,000 citations of our products since our company establishment,” Dr. Jason Li, CEO.

Proteintech Group was founded in early 2001 by a small group of scientists including its current CEO, Dr. Jason Li. The founders set out with a vision to produce an antibody for every single protein coded in the human genome. Comprehensive coverage of all human gene products is a massive undertaking, but critical because it is difficult for researchers to predict which targets may be required to further scientific studies. With antibodies for two-thirds of the human genome, Proteintech has the largest self-manufactured target coverage of all antibody companies.

Over the last 20 years, Proteintech has grown in their global reach. With locations in the US, UK, Germany, Singapore, China and Japan, Proteintech is able to provide fast delivery around the world.

  • In April 2018, Proteintech acquired Humanzyme™, a Chicago based manufacturer of human cell-expressed proteins.
  • In 2020, Proteintech acquired ChromoTek, a Munich-based manufacturer of camelid, single-domain antibodies, also known as nanobodies.

Now with over 300 employees worldwide, Proteintech is setting their sights on continuing to support the future of science with quality, transparency, and customer needs in mind.


Read the official press release here.

Munich, June 2021